291 related articles for article (PubMed ID: 16585203)
1. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
[TBL] [Abstract][Full Text] [Related]
2. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
Hu M; Wang J; Chen P; Reilly RM
Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
[TBL] [Abstract][Full Text] [Related]
4. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Kunz C; Borghouts C; Buerger C; Groner B
Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
[TBL] [Abstract][Full Text] [Related]
5. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
[TBL] [Abstract][Full Text] [Related]
6. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Jani JP; Finn RS; Campbell M; Coleman KG; Connell RD; Currier N; Emerson EO; Floyd E; Harriman S; Kath JC; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Ralston S; Rossi AM; Steyn SJ; Wagner L; Winter SM; Bhattacharya SK
Cancer Res; 2007 Oct; 67(20):9887-93. PubMed ID: 17942920
[TBL] [Abstract][Full Text] [Related]
7. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate.
Govindarajan S; Sivakumar J; Garimidi P; Rangaraj N; Kumar JM; Rao NM; Gopal V
Biomaterials; 2012 Mar; 33(8):2570-82. PubMed ID: 22192536
[TBL] [Abstract][Full Text] [Related]
8. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
9. A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression.
Wang XF; Birringer M; Dong LF; Veprek P; Low P; Swettenham E; Stantic M; Yuan LH; Zobalova R; Wu K; Ledvina M; Ralph SJ; Neuzil J
Cancer Res; 2007 Apr; 67(7):3337-44. PubMed ID: 17409443
[TBL] [Abstract][Full Text] [Related]
10. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.
Jing N; Li Y; Xiong W; Sha W; Jing L; Tweardy DJ
Cancer Res; 2004 Sep; 64(18):6603-9. PubMed ID: 15374974
[TBL] [Abstract][Full Text] [Related]
11. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.
Lee C; Dhillon J; Wang MY; Gao Y; Hu K; Park E; Astanehe A; Hung MC; Eirew P; Eaves CJ; Dunn SE
Cancer Res; 2008 Nov; 68(21):8661-6. PubMed ID: 18974106
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide, EC-1.
Li P; Jiang S; Pero SC; Oligino L; Krag DN; Michejda CJ; Roller PP
Biopolymers; 2007 Nov; 87(4):225-30. PubMed ID: 17879382
[TBL] [Abstract][Full Text] [Related]
13. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
Ishii Y; Waxman S; Germain D
Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
[TBL] [Abstract][Full Text] [Related]
15. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
Savellano MD; Pogue BW; Hoopes PJ; Vitetta ES; Paulsen KD
Cancer Res; 2005 Jul; 65(14):6371-9. PubMed ID: 16024640
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.
Zhao YH; Zhou M; Liu H; Ding Y; Khong HT; Yu D; Fodstad O; Tan M
Oncogene; 2009 Oct; 28(42):3689-701. PubMed ID: 19668225
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.
Yu D; Hung MC
Oncogene; 2000 Dec; 19(53):6115-21. PubMed ID: 11156524
[TBL] [Abstract][Full Text] [Related]
18. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
19. A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth.
Kawa S; Matsushita H; Ohbayashi H; Semba K; Yamamoto T
Biochem Biophys Res Commun; 2009 Jul; 384(3):329-33. PubMed ID: 19409371
[TBL] [Abstract][Full Text] [Related]
20. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
